Founded in Doylestown, United States, Evrys Bio is dedicated to revolutionizing antiviral therapy by targeting sirtuins, special human proteins that enhance the body's natural ability to fight infections. The company's core mission is to develop unique antiviral treatments that leverage these proteins to combat a broad spectrum of viral diseases. Evrys Bio's innovative approach focuses on creating allosteric inhibitors of sirtuin 2, which have shown promise in blocking the establishment and transcriptional activity of viruses like hepatitis B and promoting the death of infected monocytes in conditions like HCMV.

Evrys Bio has garnered attention for its groundbreaking research and development in antiviral therapies. The company has published significant findings, such as the efficacy of their SIRT2 modulators in combating various viral infections. While specific notable affiliated people and investors are not detailed, the company's achievements in advancing antiviral treatments have positioned it as a key player in the biotech industry. Evrys Bio's impact lies in its potential to offer new, effective solutions for managing and treating viral infections, thereby improving public health outcomes globally.